Моше Гат

Научные публикации

• Immune Therapies in AL Amyloidosis-A Glimpse to the Future
• Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question
• Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
• Pathway for the Diagnosis and Management of Cardiac Amyloidosis
• Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
• Amyloidogenic light chains impair plasma cell survival
• Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
• Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related Amyloidosis
• Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma
• Venetoclax in Relapse/Refractory AL Amyloidosis-A Multicenter International Retrospective Real-World Study
• Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma
• An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma
• Do older patients truly benefit from advances in myeloma care?
• Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
• Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
• Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group
• Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
• Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib
• Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study
• CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival
• Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma
• Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
• Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
• Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study
• Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
• Suppression of multiple myeloma by mitochondrial targeting
• Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
• Serum Hevylite^® assay in the differential diagnosis of patients with high suspicion of AL Amyloidosis
• Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study
• Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma
• Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
• Neurological misdiagnoses of lymphoma
• The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data
• Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study
• Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study
• Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study
• The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression
• Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients
• Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma
• Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse
• Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
• A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
• The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis
• Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study
• Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome
• Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
• Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature
• Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy
• The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma
• Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy
• Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
• A Randomized Controlled Study to Determine the Efficacy of Garlic Compounds in Patients With Hematological Malignancies at Risk for Chemotherapy-Related Febrile Neutropenia
• Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation
• Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment
• Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome
• Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients
• Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia
• Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma
• Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort
• Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia
• Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients
• TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity
• Increased risk of central venous catheter-associated thrombosis in acute promyelocytic leukemia: a single-institution experience
• Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study
• Light chain amyloidosis 2012: a new era
• High incidence of skin rash in patients with hairy cell leukemia treated with cladribine
• MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma
• Central nervous system prophylaxis in mantle cell lymphoma
• BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells
• Prolonged fever, hepatosplenomegaly, and pancytopenia in a 46-year-old woman
• Clinical problem-solving. A fractured diagnosis
• Is prolonged immobilization a risk factor for symptomatic venous thromboembolism in elderly bedridden patients? Results of a historical-cohort study
• Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis
• Chest radiographs in the emergency department: is the radiologist really necessary?
• Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein
• Acute myocardial infarction after bone marrow transplantation: an unsuspected late complication
• Treatment of tobacco use and dependence
• Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils